Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

Description

This study is an observational study of blood and tissue biomarkers. Investigators plan to evaluate the accuracy of lung cancer biomarkers found in the blood in determining if a lung nodule is cancer or benign. Investigators also plan to examine another biomarker found in the tumor tissue to identify participants after lung cancer surgery who have a high risk for recurrent cancer. Finally, investigators plan to determine if one of the blood-based biomarkers can be used to detect any late cancer recurrence.

Conditions

Lung; Node, Adenocarcinoma of Lung

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is an observational study of blood and tissue biomarkers. Investigators plan to evaluate the accuracy of lung cancer biomarkers found in the blood in determining if a lung nodule is cancer or benign. Investigators also plan to examine another biomarker found in the tumor tissue to identify participants after lung cancer surgery who have a high risk for recurrent cancer. Finally, investigators plan to determine if one of the blood-based biomarkers can be used to detect any late cancer recurrence.

Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

Condition
Lung; Node
Intervention / Treatment

-

Contacts and Locations

Tampa

Moffitt Cancer Center, Tampa, Florida, United States, 33612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Potentially-resectable lung nodule 8-40 mm diameter suspected (no preop diagnosis) of being a clinically node-negative lung cancer \[clinical stage IA-IB (cT1a-T2aN0), \<4cm diameter\].
  • * If surgical resection is recommended, patient will undergo surgery at Moffitt Cancer Center.
  • * If a definite tissue diagnosis is obtained and stereotactic body radiotherapy (SBRT) is the recommended treatment instead of surgery, the SBRT will be delivered at Moffitt Cancer Center.
  • * \>18 years old, male or female.
  • * ECOG performance status 0-1.
  • * Agree to participate in the follow-up protocol.
  • * Any suspected primary lung cancer cell type (except a suspected typical carcinoid tumor, carcinoma in situ or minimally-invasive carcinoma).
  • * Ability to understand and the willingness to sign a written, informed consent document.
  • * Participants who are actively receiving any cancer treatment.
  • * Participants with uncontrolled intercurrent illness.
  • * Prior lung cancer within 5 years.
  • * Current active other major cancer except non-melanoma skin cancer.
  • * Patients with pure ground glass opacities (nodules) or hilar masses.
  • * Suspected typical carcinoid cell type (well-differentiated neuroendocrine carcinoma).
  • * Metastatic nodule (suspected) in the lung from an extrapulmonary cancer.
  • * Patient unable to provide informed consent.
  • * Prisoner or incarcerated individual.
  • * For surgical patients, a R1 or R2 resection.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

H. Lee Moffitt Cancer Center and Research Institute,

Lary A Robinson, MD, PRINCIPAL_INVESTIGATOR, Moffitt Cancer Center

Study Record Dates

2028-02